-
1 Comment
BIOLASE, Inc is currently in a long term downtrend where the price is trading 5.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
BIOLASE, Inc's total revenue sank by 16.3% to $9M since the same quarter in the previous year.
Its net income has dropped by 71.2% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 71.2% to $-1M since the same quarter in the previous year.
Based on the above factors, BIOLASE, Inc gets an overall score of 2/5.
ISIN | US0909112072 |
---|---|
Sector | Healthcare |
Industry | Medical Devices |
Exchange | NASDAQ |
CurrencyCode | USD |
Beta | 0.68 |
---|---|
Market Cap | 439K |
PE Ratio | 0.0 |
Target Price | 1.2 |
Dividend Yield | None |
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California. On October 1, 2024, BIOLASE, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BIOL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025